Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    b2355
Show Display Options
Rank Status Study
1 Completed
Has Results
Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol;   Drug: Placebo to indacaterol
2 Recruiting Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Conditions: Diffuse Large B-cell Lymphoma;   de Novo DLBCL;   DLBCL Transformed From Indolent Lymphoma;   Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab;   Drug: Gemcitabine + Rituximab
3 Recruiting Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Procedure: Lenalidomide and dexamethasone for four 28-day cycles with or without autologous peripheral blood stem cell transplant.

Indicates status has not been verified in more than two years